MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Johnson & Johnson Book Value 2011-2026 | JNJ
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Johnson & Johnson
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 81.5 B | 71.5 B | 68.8 B | 74 B | 63.3 B | - | 59.5 B | 59.8 B | 70.4 B | 71.2 B | - | 69.8 B | 74.1 B | 57.1 B | 56.6 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 81.5 B | 56.6 B | 67.5 B |
Quarterly Book Value Johnson & Johnson
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 79.3 B | 78.5 B | 78.1 B | 70.2 B | 71.5 B | 70 B | 71.2 B | 76.4 B | 70.9 B | 76.8 B | 74.6 B | - | 74.7 B | 63.3 B | 70.3 B | 69.6 B | 65.8 B | - | 64.5 B | 63 B | 61.3 B | 59.5 B | 59.5 B | 59.5 B | 59.5 B | 59.8 B | 59.8 B | 59.8 B | 59.8 B | 60.2 B | 60.2 B | 60.2 B | 60.2 B | 71.2 B | 72.8 B | 72.5 B | 72.6 B | - | 71.6 B | 71.1 B | 67.9 B | 69.8 B | 69.8 B | 69.8 B | 69.8 B | 74.1 B | 74.1 B | 74.1 B | 74.1 B | 64.8 B | 64.8 B | 64.8 B | 64.8 B | 56.6 B | 61.5 B | 62.1 B | 59.9 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 79.3 B | 56.6 B | 67.4 B |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M |  Germany |
 |
Grifols, S.A.
GRFS
|
8.61 B | $ 7.68 | - | $ 6.83 B |  Spain |
 |
Altimmune
ALT
|
225 M | $ 3.47 | 3.74 % | $ 306 M |  USA |
 |
Amgen
AMGN
|
90.6 B | - | - | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
789 M | - | - | $ 915 M | USA |
 |
I-Mab
IMAB
|
5.63 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
282 M | - | 2.54 % | $ 160 B |  France |
 |
Heron Therapeutics
HRTX
|
14.3 M | - | - | $ 130 M | USA |
 |
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-163 M | $ 218.0 | -1.75 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
8.32 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.2 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
5.36 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - |  Russia |
 |
Incyte Corporation
INCY
|
5.17 B | $ 90.75 | -0.03 % | $ 17.7 B | USA |
 |
Inovio Pharmaceuticals
INO
|
117 M | $ 1.57 | -0.63 % | $ 34.8 M | USA |
 |
Avenue Therapeutics
ATXI
|
1.86 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
409 M | $ 12.91 | 1.33 % | $ 778 M | USA |
 |
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Inventiva S.A.
IVA
|
-107 M | $ 6.11 | 5.71 % | $ 138 M | France |
 |
Calithera Biosciences
CALA
|
49.1 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
57.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
-12.6 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-279 M | - | -7.23 % | $ 13 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
251 M | $ 16.73 | -1.59 % | $ 831 M | Britain |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Denali Therapeutics
DNLI
|
1.23 B | $ 21.04 | 4.31 % | $ 3.46 B | USA |
 |
Kamada Ltd.
KMDA
|
319 M | $ 8.27 | 0.24 % | $ 260 M | Israel |
 |
Karyopharm Therapeutics
KPTI
|
-186 M | $ 6.93 | -9.17 % | $ 845 K | USA |
 |
Keros Therapeutics
KROS
|
303 M | $ 11.17 | 1.92 % | $ 416 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
106 M | $ 4.3 | 1.37 % | $ 714 M | Canada |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |